An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Authors:
- Paul JankPJPaul Jank
- Thomas KarnTKThomas Karn
- Marion van MackelenberghMMMarion van Mackelenbergh
- Judith LindnerJLJudith Lindner
- Denise TreueDTDenise Treue
- Jens HuoberJHJens Huober
- Knut EngelsKEKnut Engels
- Christine SolbachCSChristine Solbach
- Kurt DieboldKDKurt Diebold
- Frederik MarméFMFrederik Marmé
- Volkmar MüllerVMVolkmar Müller
- Andreas SchneeweissASAndreas Schneeweiss
- 5 June 2024
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (17) , 3868-3880
Abstract
Purpose: The PI3K signaling pathway is frequently dysregulated in breast cancer, and mutations in PIK3CA are relevant for therapy resistance in HER2-positive (HER2pos) breast cancer. Mutations in exons 9 or 20 may have different impacts on response to neoadjuvant chemotherapy-based treatment regimens. Experimental Design: We investigated PIK3CA mutations in 1,691 patients with early breast cancer who were randomized into four neoadjuvant multicenter trials: GeparQuattro (NCT00288002), GeparQuinto (NCT00567554), GeparSixto (NCT01426880), and GeparSepto (NCT01583426). The role of different PIK3CA exons and hotspots for pathologic complete response (pCR) following neoadjuvant chemotherapy (NACT) and patient survival were evaluated for distinct molecular subgroups and anti-HER2 treatment procedures. Results: A total of 302 patients (17.9%) of the full cohort of 1,691 patients had a tumor with a PIK3CA mutation, with a different prevalence in molecular subgroups: luminal/HER2-negative (HER2neg) 95 of 404 (23.5%), HER2pos 170 of 819 (20.8%), and triple-negative breast cancer 37 of 468 patients (7.9%). We identified the mutations in PIK3CA exon 20 to be linked with worse response to anti-HER2 treatment (OR = 0.507; 95% confidence interval, 0.320–0.802; P = 0.004), especially in hormone receptor–positive HER2-positive breast cancer (OR = 0.445; 95% confidence interval, 0.237–0.837; P = 0.012). In contrast, exon 9 hotspot mutations p.E452K and p.E545K revealed no noteworthy differences in response therapy. Luminal/HER2neg patients show a trend to have worse treatment response when PIK3CA was mutated. Interestingly, patients with residual disease following neoadjuvant treatment had better survival rates when PIK3CA was mutated. Conclusions: The PIK3CA hotspot mutation p.H1047R is associated with worse pCR rates following NACT in HER2pos breast cancer, whereas hotspot mutations in exon 9 seem to have less impact.Keywords
All Related Versions
Funding Information
- Bundesministerium für Forschung, Technologie und Raumfahrt (SATURN3, ID: 01KD2206M)
This publication has 59 references indexed in Scilit:
- Development of small-molecule inhibitors that target PI3KβDrug Discovery Today, 2023
- Isoform-selective targeting of PI3K: time to consider new opportunities?Trends in Pharmacological Sciences, 2023
- Discordance of PIK3CA mutational status between primary and metastatic breast cancer: a systematic review and meta-analysisBreast Cancer Research and Treatment, 2023
- Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancerBreast Cancer Research and Treatment, 2023
- PIK3CA-mutations in breast cancerBreast Cancer Research and Treatment, 2022
- 200TiP A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC)- GeparPiPPaAnnals of Oncology, 2022
- Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancerAnnals of Oncology, 2020
- Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapyBreast Cancer Research and Treatment, 2018
- Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancerBreast Cancer Research and Treatment, 2017
- PDK1, the master regulator of AGC kinase signal transductionSeminars in Cell & Developmental Biology, 2004